Location History:
- Deubendorf, CH (2017)
- Duebendorf, CH (2014 - 2019)
- Dübendorf, CH (2011 - 2022)
- Dubendorf, CH (2016 - 2023)
Company Filing History:
24 out of 97 
16 out of 16 
10 out of 12 
Years Active: 2011-2025
Title: Jan Grimm: Innovator in Antibody-Based Therapies
Introduction
Jan Grimm, based in Dübendorf, Switzerland, is a prominent inventor with an impressive portfolio of 38 patents. His work primarily focuses on antibody-based therapies, particularly in the context of amyloidosis and other neurodegenerative diseases. Grimm's contributions to the field of biotechnology have the potential to significantly impact diagnostics and patient treatment methodologies.
Latest Patents
Two of Jan Grimm's latest patents showcase his innovative approach to tackling transthyretin (TTR) amyloidosis. The first patent details human-derived antibodies specific for transthyretin, which are capable of binding misfolded, misassembled, and aggregated TTR species. This invention also includes methods for diagnosing and monitoring diseases linked to TTR amyloidosis, along with assays and kits for TTR-related antibodies. These anti-TTR antibodies have applicable uses in pharmaceutical and diagnostic compositions aimed at TTR-targeted immunotherapy.
The second patent introduces novel dipeptide repeat (DPR) specific antibodies, including human-derived options and their synthetic variants. These antibodies can bind C9orf72 poly-glycine-alanine DPRs, contributing to advancements in immunotherapy and diagnostics related to DPR protein-targeted conditions.
Career Highlights
Jan Grimm has worked with notable organizations, including Neurimmune Holding AG and the University of Zurich. Throughout his career, he has been dedicated to advancing the understanding and treatment of neurodegenerative diseases through innovative antibody therapies and diagnostics. His expertise and research initiatives continue to foster growth and development in the field of biomedical research.
Collaborations
Grimm's collaborations with esteemed professionals such as Roger Nitsch and Christoph Hock have further enriched his research endeavors. These partnerships aim to promote knowledge sharing and encourage breakthroughs in immunotherapy solutions. Teamwork and collaboration have played crucial roles in driving forward the innovations that Grimm contributes to the scientific community.
Conclusion
Jan Grimm's work epitomizes the ingenuity and dedication of modern inventors in the realm of biotechnology. Through his groundbreaking patents and collaborations, he is redefining the landscape of antibody-based therapies for complex diseases. As he continues to push the boundaries of scientific inquiry, Jan Grimm remains a pivotal figure in the ongoing evolution of medical innovation.